Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the migraine inducing effect of levcromakalim in patients with migraine with aura.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Headache Center
• Treatments: Cromakalim

Criteria

Inclusion Criteria:

• Migraine with aura patients of both sexes.

• 18-60 years.

• 50-100 kg.

Exclusion Criteria:

• Headache less than 48 hours before the tests start

• Daily consumption of drugs of any kind that investigator deems might affect study results or safety.

• Pregnant or nursing women.

• Cardiovascular disease of any kind, including cerebrovascular diseases.

• Tension type headache (TTH) according to International Classification of Headache Disorders version 3 more than 5 times a month on average during the past year

• Known cluster headache according to International Classification of Headache Disorders version 3.

• Psychiatric disorder

• Smoking or abuse of drugs or alcohol

• Hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg) on day of inclusion.

• Hypotension (systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg) on day of inclusion.